部分页面内容可能有英文版。

TAS7500SU

Terahertz Spectroscopic Analysis System TAS7500 Series

Wideband Terahertz Spectroscopic System for wideband spectroscopic analysis in the terahertz frequency range

  • A newly developed Cherenkov terahertz source delivers dramatically improved high-frequency capabilities, supporting spectroscopic measurement up to 7THz
  • Highly stable spectral power is ideal for terahertz research
  • Supports measurement of pharmaceuticals in liquid, solid, and powder forms
  • Easy module switching requires no adjustments
  • Attached dry air unit eliminates moisture interference
Supported measurement modules (Option) Transmission / reflection / ATR
Target materials Pharmaceutical tablets / liquids / powders, other reagents, chemical substances
Analysis / display functions Spectral display (transmittance, reflectance, ATR, phase shift, absorbance, absorption coefficient, complex refractive index, complex permittivity), time response display (electric field strength), quantitative analysis (optional)
Frequency range* 0.5-7THz (Transmission / reflection mode)
0.5-6.5THz (ATR mode)
Scan rate <8ms / scan
  • *
    at 23°C ±5°C

Application Pharmaceutical: Crystalline/Amorphous Analysis

Analysis of crystal polymorphism

THz spectroscopy has many applications in the development of various healthcare products. Absorption in the THz frequency range is sensitive to crystal lattice vibrations. These absorptions provide a characteristic spectrum of the crystal forms, thus enabling a new method for analyzing polymorphs.

Example of transmission measurement of crystal polymorph with THz waves (*1), (*2)

Compound A(*3) has a crystal polymorph that is difficult to distinguish by a PXRD analysis. Using THz spectroscopy, the crystal forms of a medicinal product can be determined and monitored in seconds.

  1. Y. Ikeda, E. Kato, K. Terada et al., Chem. Pharm. Bull., 58 (2010) 76.
  2. Y. Ikeda, E. Kato, K. Terada et al., Proceedings of the 25th Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan (2010) 201
  3. Provided by Takeda Pharmaceutical Company Limited.

Crystallinity

Using a TAS7500 system to observe the crystallization process of non-crystalline indomethacin (100%) over a 10-day period, the phase transition into the γ-crystalline form is confirmed.

ExcelPDF